This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wallaschofski, H. Articles by Lohmann, T. Search for Related Content PubMed PubMed Citation Articles by Wallaschofski, H. Articles by Lohmann, T.

PRL as a Novel Potent Cofactor for Platelet Aggregation

Department of Biochemistry, University of Wurzburg (M.E.), 97070 Wurzburg, Germany; and Departments of Internal Medicine I (M.D., M.K.) and III (H.W., T.L.), Institute for Medical Informatics, Statistics, and Epidemiology (B.H.), and Department of Obstetrics and Gynecology (R.F., H.S.), University of Leipzig, D-04103 Leipzig, Germany

Address all correspondence and requests for reprints to: Prof. Tobias Lohmann, Department of Medicine I, University of Erlangen, Krankenhausstr. 12, 91 023 Erlangen, Germany. E-mail: Tobias.Lohmann{at}med1.imed.uni-erlangen.de

Abstract

Pregnancy (including puerperium) is a period of hypercoagulability and seems to be an independent major risk factor for venous thromboembolism (VTE). However, the basis of the increased risk of VTE in pregnancy and around delivery is unknown. We hypothesized that changes in PRL, which is a prominently increased hormone during pregnancy and lactation, might be involved in the activation of platelets.

To investigate platelet functional abnormalities in pregnancy, we assessed the ADP-stimulated and nonstimulated P-selectin expression of platelets in 42 consecutive pregnant women, 22 normo- and hyperprolactinemic patients with pituitary tumors, and controls. In addition, the aggregation of platelets by human PRL in vitro was studied. We found a significant correlation between PRL values and ADP stimulation of platelets in pregnant women (r = 0.56; P < 0.0001) and patients with pituitary tumors (r = 0.57; P = 0.006). Hyperprolactinemic pregnant women or hyperprolactinemic patients with pituitary tumors revealed significantly higher ADP stimulation of platelets (P < 0.0001) than healthy controls or normoprolactinemic patients with pituitary tumors. These results were reconciled by increased in vitro stimulation and aggregation of platelets using human PRL.

Our novel findings demonstrate that hyperprolactinemia causes increased platelet aggregation via ADP stimulation both in vitro and in vivo. Moreover, our data indicate that PRL may be a physiological cofactor of the delicate coagulation balance during pregnancy and puerperium that might explain the increased risk of VTE in pregnant women around delivery. Further studies of the interaction between PRL and platelets will clarify the clinical relevance of hyperprolactinemia as a potential risk factor for VTE.

This article has been cited by other articles:

				S D Treadwell, B Thanvi, and T G Robinson Stroke in pregnancy and the puerperium Postgrad. Med. J., May 1, 2008; 84(991): 238 - 245. [Abstract] [Full Text] [PDF]

				I. Mertens, R. V Considine, M. Van der Planken, and L. F Van Gaal Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur. J. Endocrinol., September 1, 2006; 155(3): 477 - 484. [Abstract] [Full Text] [PDF]

				J. H. Friedman Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology, August 22, 2006; 67(4): 564 - 566. [Abstract] [Full Text] [PDF]

				S. S Gill, P. A Rochon, N. Herrmann, P. E Lee, K. Sykora, N. Gunraj, S.-L. T Normand, J. H Gurwitz, C. Marras, W. P Wodchis, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study BMJ, February 26, 2005; 330(7489): 445. [Abstract] [Full Text] [PDF]